Treatments

  • Hysterectomy

    Depending on the extent of your cancer, a hysterectomy removes all or part of the uterus and may include surrounding structures. Currently, 80 to 90 percent of hysterectomies are done robotically. Depending on your individual situation, your surgeon may recommend that you receive radiation therapy or hormone therapy to kill any remaining cancer cells.

  • Sentinel Node Biopsy

    The cancer is most likely to spread from the tumor to the sentinel lymph node. A dye is injected near the tumor and flows through the lymph ducts to the lymph nodes. Because the dyes make the sentinel nodes glow under special goggles, sentinel node detection has risen to 95 percent or greater. Researchers at Sylvester are leading international trials to validate the role of sentinel node biopsy in vulvar cancer.

  • External Radiation Therapy 

    This therapy sends high levels of radiation straight to the cancer cells. Since radiation is used to kill cancer cells and to shrink tumors, your specialist will use special shields to protect the tissue surrounding the treatment area.

  • Internal Radiation Therapy 

    Radiation therapy is given as close to the cancer as possible, at times inside the body. For low-risk tumors, vaginal brachytherapy may be used. Intermediate risk may require both brachytherapy and some external radiation therapy. In high-risk patients, radiation therapy may be given with chemotherapy. That's why you want gynecologic radiation specialists at Sylvester planning your treatment.

  • Chemotherapy

    This therapy is a combination of cancer-fighting drugs that can be administered intravenously to kill any remaining cancer cells in the body.

  • Hormone Therapy

    Some cancer cells require hormones to grow. Hormone therapy is used to stop that growth. Medicines can reduce these hormones in the body. Medicines may block these hormones and keep them from working in cancer cells.

  • Targeted Therapy

    Drugs are used to identify and attack specific cancer cells without harming normal cells. Several targeted therapies have been approved by FDA and may include:

    • Antiangiogenesis Agents: These are agents that prevent the tumor from forming new blood vessels to feed it. Several are being studied in clinical trials.

    • Mammalian Target of Rapamycin (mTOR) Inhibitors: In cancer, mTOR is frequently hyper-activated which promotes cancer development and progression. In certain cancers, it creates resistance to chemotherapy. Research on this therapy looks promising.